Pierre-Louis Tharaux, PARCC – Paris Cardiovascular Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), 56 rue Leblanc, 75015 Paris, France.
Current Position
Inserm Research Professor and Team leader, Paris Cardiovascular Research Centre – PARCC, 56 rue Leblanc, 75015 Paris and lecturer (AP-HP-Inserm) at the Nephrology Department, Hôpital Européen Georges Pompidou (HEGP), Paris.
Contact
Telephone: +33 6 89 50 29 48 (mobile)
Fax: +33 1 53 98 79 53
E-Mail: pierre-louis.tharaux@inserm.fr
Education and Training
– Medical studies at Faculté Necker-Enfants Malades- Université Paris 5-René Descartes (1983-1990).
– Interne des Hôpitaux de Paris (1991)(rank : 48/6500)
-Fellowship in Nephrology (1991-1998). Nephrology: Board Certified (1998).
-Medical Doctorate from University Paris Descartes (1998). Suma cum laude
-PhD. in Physiology & Pathophysiology from University Pierre & Marie Curie (2000), Paris. Suma cum laude.
– Curriculum in pathophysiology of sleep and cardiovascular disorders, University Paris Sud (2000).
Professional Experience
1990-1996 : “Internat de Médecine” (Residency and Fellowship equivalent) in Paris : (ICU, nephrology, hepatology, endocrinology, physiology).
1997-2000 : Research: Internat of Paris Fellowship, Silver medal award of Assistance Publique-Hôpitaux de Paris, INSERM fellowship for biomedical research.
2000-2002 : Research Associate, Duke University Medical Center, Durham, NC, Dr Thomas M Coffman laboratory and Curriculum in Genetics, University of North Carolina, Dr Beverly Koller lab. Fellow of the Simone and Cino del Duca Fundation and Elli-Lilly International fellow.
2002- present: INSERM Investigator and contractor with Assistance Publique-Hopitaux de Paris (AP-HP). Goal: To conduct translational research from preclinical to clinical fields in Sickle Cell Disease Nephropathy and in Glomerular diseases.
2009- present: Inserm Research Director (Research Professor) and team leader, Paris Cardiovascular Research Center @ HEGP, Inserm.
Honors-Awards
-Année-Recherche de l’Internat (Research fellowship for excellence in Medicine) – 1995
-Silver medal for Interns in Paris Public teaching hospitals, AP-HP, 1997
-INSERM fellowship for biomedical research (poste d’accueil) – 1998
-Louis Auquier / AP-HP award for Academic Achievement in Medicine – 1999
-European Society of Microcirculation Young Investigator award- 1999
-Fondation Simone et Cino del Duca fellowship for research – 2000-2001
-Elli-Lilly International Research Fellow – 2000
– Gordon Research Conference on Angiotensin, best communication award 2007.
– European Research Council Starting Grant award 2012
– Eloi Collery Prize of the French National Academy of Medicine – 2013
– FRIAS Senior Fellow, Freiburg Institute for Advanced Studies (FRIAS), University of Freiburg, Germany -2015
Scientific interests: Pathophysiology of the microcirculation
As an ERC Investigator, Pierre-Louis Tharaux performs high risk/high potential benefit research in areas of major medical need.
Research in our laboratory is centered on the analysis of mouse vascular and renal pathophysiology with translation to clinical studies, with a particular emphasis on genes or pathways implicated in disease tolerance. Our work covers:
1- GPCRs and RTK signaling and metabolism in kidney and vascular cells (podocytes and endothelial cells) in accelerated ageing, focal segmental glomerulosclerosis (FSGS) and hypertension. Our goal is to promote tolerance of the kidney and the microcirculation to immune injury (vasculitides), metabolic injury (diabetes) and hypertension.
2- Innate immunity in Sickle Cell Sickle Cell Nephropathy and Vasculopathy and Crescentic RPGN.
3-Interested in drug repositioning and new drug development, including miRNA targeting for glomerular diseases and sickle cell disease.
Reviewer, Committees
2002-2006 American Heart Association, Fellowship Peer Review
2003-2007 Nominated Member of Inserm (Institut National de la Santé et de la Recherche
Médicale) Scientific Council and committee for recruitments and evaluation of team applications.
2007-present Member of the INSERM Avenir program selection committee.
2007-2010 Member of the Scientific Program Committee for the World Congress of Nephrology (International Society of Nephrology)
2010-2012 Member of the Scientific Program Committee for the European Renal Association (ERA-EDTA) meeting.
2011: Member of the Scientific and Organizing Committee of 12th International Conference on Endothelin, Sept 2011, Cambridge, UK.
2013: Member of the Scientific and Organizing Committee of 13th International Conference on Endothelin, Sept 2013, Tokyo, Japan.
Reviewer for The Journal of the American Society of Nephrology; The Journal Clinical Investigation; Kidney International; Circulation, Arteriosclerosis; Blood; Thrombosis and Vascular Biology; The American Journal of Physiology; Nature Medicine.
Grants
* 2013-2018 European Research Council (ERC) Starting Grant. “Target Glomerular Diseases”. 1.3 M€
* 2015-2018 ANR BIOCADRE Study: “Mechanistic and biological mechanisms of chronic vasculopathy
in sickle cell disease”. 150 k€
* 2015-2016 Fondation de France. « Vasculophagy : Rôle de l’autophagie endothéliale dans la maladie microvasculaire du diabète ». 90 k€
* 2015-2016 French Foundation for Rare Diseases. Preclinical research in rare diseases: translational steps in large animals. “Treatment of rapidly progressive glomerulonephritis by powerful inhibitors of HB-EGF and miRNA92a pathways in pig”. 100 k€
*Active
Original publications in peer reviewed journals and patents:
Endothelial Epas1 deficiency is sufficient to promote parietal epithelial cell activation and FSGS in experimental hypertension.
Luque Y*, Lenoir O*, Bonnin P, Hardy L, Chipont A, Placier S, Vandermeersch S, Xu-Dubois Y-C, Robin B, Lazareth H, Souyri M, Guyonnet L, Baudrie V, Camerer E, Rondeau E, Mesnard L, Tharaux P-L.
J Am Soc Nephrol. In press
Endothelium-Neutrophil Communication via B1-Kinin Receptor-Bearing Microvesicles in Vasculitis.
Tharaux PL, Dhaun N.
J Am Soc Nephrol. 2017 Jul 14. pii: ASN.2017030300.
The endothelin B receptor plays a crucial role for the adhesion of neutrophils to the endothelium in sickle cell disease.
Koehl B, Nivoit P, El Nemer W, Lenoir O, Hermand P, Pereira C, Brousse V, Guyonnet L, Ghinatti G, Benkerrou M, Colin Y, Le Van Kim C, Tharaux PL.
Haematologica. 2017 Apr 6. pii:
Sildenafil Prevents Podocyte Injury via PPAR-γ-Mediated TRPC6 Inhibition.
Sonneveld R, Hoenderop JG, Isidori AM, Henique C, Dijkman HB, Berden JH, Tharaux PL, van der Vlag J, Nijenhuis T.
J Am Soc Nephrol. 2017;28(5):1491-1505.
Targeting mTOR Signaling Can Prevent the Progression of FSGS.
Zschiedrich S, Bork T, Liang W, Wanner N, Eulenbruch K, Munder S, Hartleben B, Kretz O, Gerber S, Simons M, Viau A, Burtin M, Wei C, Reiser J, Herbach N, Rastaldi MP, Cohen CD, Tharaux PL, Terzi F, Walz G, Gödel M, Huber TB.
J Am Soc Nephrol. 2017;28(7):2144-2157.
Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1.
Lee HW, Khan SQ, Khaliqdina S, Altintas MM, Grahammer F, Zhao JL, Koh KH, Tardi NJ, Faridi MH, Geraghty T, Cimbaluk DJ, Susztak K, Moita LF, Baltimore D, Tharaux PL, Huber TB, Kretzler M, Bitzer M, Reiser J, Gupta V.
J Biol Chem. 2017;292(2):732-747.
Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.
Suarez-Alvarez B, Morgado-Pascual JL, Rayego-Mateos S, Rodriguez RM, Rodrigues-Diez R, Cannata-Ortiz P, Sanz AB, Egido J, Tharaux PL, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M.
J Am Soc Nephrol. 2016 Jul 19. pii: ASN.2015080910
Efficient second-harmonic imaging of collagen in histological slides using Bessel beam excitation.
Vuillemin N, Mahou P, Débarre D, Gacoin T, Tharaux PL, Schanne-Klein MC, Supatto W, Beaurepaire E.
Sci Rep. 2016;6:29863. doi: 10.1038/srep29863.
Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption of the Glomerular Glycocalyx.
Garsen M, Lenoir O, Rops AL, Dijkman HB, Willemsen B, van Kuppevelt TH, Rabelink TJ, Berden JH, Tharaux PL, van der Vlag J.
J Am Soc Nephrol. 2016. pii: ASN.2015091070.
Delayed Healing of Sickle Cell Ulcers Is due to Impaired Angiogenesis and CXCL12 Secretion in Skin Wounds.
Nguyen VT, Nassar D, Batteux F, Raymond K, Tharaux PL, Aractingi S.
J Invest Dermatol. 2016;136(2):497-506. doi: 10.1016/j.jid.2015.11.005.
How Is Proteinuric Diabetic Nephropathy Caused by Disturbed Proteostasis and Autophagy in Podocytes?
Tharaux PL, Huber TB.
Diabetes. 2016;65(3):539-41. doi: 10.2337/dbi15-0026.
Platelet and Erythrocyte Sources of S1P Are Redundant for Vascular Development and Homeostasis, but Both Rendered Essential After Plasma S1P Depletion in Anaphylactic Shock.
Gazit SL, Mariko B, Thérond P, Decouture B, Xiong Y, Couty L, Bonnin P, Baudrie V, Le Gall SM, Dizier B, Zoghdani N, Ransinan J, Hamilton JR, Gaussem P, Tharaux PL, Chun J, Coughlin SR, Bachelot-Loza C, Hla T, Ho-Tin-Noé B, Camerer E.
Circ Res. 2016;119(8):e110-26.
Angiogenin Mediates Cell-Autonomous Translational Control under Endoplasmic Reticulum Stress and Attenuates Kidney Injury.
Mami I, Bouvier N, El Karoui K, Gallazzini M, Rabant M, Laurent-Puig P, Li S, Tharaux PL, Beaune P, Thervet E, Chevet E, Hu GF, Pallet N.
J Am Soc Nephrol. 2016;27(3):863-76. doi: 10.1681/ASN.2015020196.
Nrf2 drives podocyte-specific PPAR expression that is essential to promote resistance to crescentic glomerulonephritis
Henique C*, Bollee G*, Lenoir O, Dhaun N, Camus M, Chipont A, Flosseau K, Mandet C, Yamamoto M, Karras A, Thervet E, Bruneval P, Nochy D, Mesnard L, Tharaux PL
J Am Soc Nephrol. 2016;27(1):172-88. doi: 10.1681/ASN.2014111080
Podocyte-Specific Deletion of Murine CXADR Does Not Impair Podocyte Development, Function or Stress Response.
Schell C, Kretz O, Bregenzer A, Rogg M, Helmstädter M, Lisewski U, Gotthardt M, Tharaux PL, Huber TB, Grahammer F.
PLoS One. 2015;10(6):e0129424. doi: 10.1371
Endothelial cell- and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis
Lenoir O , Jasiek M, Hénique C, Guyonnet L, Hartleben B, Bork T, Chipont A, Flosseau K, Bensaada I, Schmitt A, Massé JM, Souyri M, Huber TB, Tharaux PL
Autophagy. 2015 ;11(7):1130-45. doi: 10.1080/15548627.2015.1049799.
Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vaso-occlusions in sickle cell disease.
Camus SM, De Moraes JA, Bonnin P, Abbyad P, Le Jeune S, Lionnet F, Loufrani L, Grimaud L, Lambry JC, Charue D, Kiger L, Renard JM, Larroque C, Le Clésiau H, Tedgui A, Bruneval P, Barja-Fidalgo C, Alexandrou A, Tharaux PL, Boulanger CM, Blanc-Brude OP.
Blood. 2015. pii: blood-2014-07-589283.
Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study.
Ranque, B, Mene A, Bara Diop I, Thia MM, , Diallo D, Diop S, Diagne I, Sanogo I, Kingue S, Chelo D, Wamba G, Diarra M, Anzouan JB, N’Guetta R, Diakité CH, Traore Y, Legueun G, Deme-Ly I, Belinga S, Boidy K, Kamara I, Tharaux PL, Jouven X.
Lancet Haematology, 2014, 1, (2), e64–e73
Regulation of the ROS Response Dynamics and Organization to PDGF Motile Stimuli Revealed by Single Nanoparticle Imaging.
Bouzigues CI, Nguyên TL, Ramodiharilafy R, Claeson A, Tharaux PL, Alexandrou A.
Chem Biol. 2014;21(5):647-56.
Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.
Lenoir O, Milon M, Virsolvy A, Hénique C, Schmitt A, Massé JM, Kotelevtsev Y, Yanagisawa M, Webb DJ, Richard S, Tharaux PL.
J Am Soc Nephrol. 2014;25(5):1050-62.
Lutheran/basal cell adhesion molecule accelerates progression of crescentic glomerulonephritis in mice.
Huang J, Filipe A, Rahuel C, Bonnin P, Mesnard L, Guérin C, Wang Y, Le Van Kim C, Colin Y, Tharaux PL.
Kidney Int. 2014;85(5):1123-36.
Genetic background-dependent thrombotic microangiopathy is related to vascular endothelial growth factor receptor 2 signaling during anti-glomerular basement membrane glomerulonephritis in mice.
Mesnard L, Cathelin D, Vandermeersch S, Rafat C, Luque Y, Sohier J, Nochy D, Garcon L, Callard P, Jouanneau C, Verpont MC, Tharaux PL, Hertig A, Rondeau E.
Am J Pathol. 2014;184(9):2438-49.
Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression.
Hochheiser K, Heuser C, Krause TA, Teteris S, Ilias A, Weisheit C, Hoss F, Tittel AP, Knolle PA, Panzer U, Engel DR, Tharaux PL, Kurts C.
J Clin Invest. 2013;123(10):4242-4254.
Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease.
Camus SM, Gausserès B, Bonnin P, Loufrani L, Grimaud L, Charue D, De Moraes JA, Renard JM, Tedgui A, Boulanger CM, Tharaux PL, Blanc-Brude OP.
Blood. 2012;120(25):5050-8.
The Epidermal Growth Factor Receptor Promotes Glomerular Injury and Renal Failure in Rapidly Progressive Crescentic Glomerulonephritis.
Bollée G and Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg Susan W, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL.
Nat Med. 2011;17(10):1242-50. doi: 10.1038/nm.2491
Sickling of red blood cells through rapid oxygen exchange in microfluidic drops
Abbyad P, Tharaux PL, Martin JL, Baroud CN, Alexandrou A
Lab Chip. 2010;10(19):2505-12
A Role for Angiotensin II Type 1 Receptors on Bone Marrow-Derived Cells in the Pathogenesis of Angiotensin II–Dependent Hypertension.
Crowley SD, Song Y-S, Sprung G, Griffiths R, Sparks M, Yan M, Burchette J-L, Howell DN, Lin EE, Okeiyi B, Stegbauer J, Yang Y, Tharaux P-L, Ruiz P.
Hypertension. 2010; 55:99-108
TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice.
Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z.
J Clin Invest. 2010;120(2):422-32.
Glomerular Hyperfiltration in Adult Sickle Cell Anemia: A Frequent Hemolysis Associated Feature.
Haymann JP, Stankovic K, Levy P, Avellino V, Tharaux PL, Letavernier E, Grateau G, Baud L, Girot R, Lionnet F.
Clin J Am Soc Nephrol. 2010;5(5):756-61
Single europium-doped nanoparticles measure temporal pattern of reactive oxygen species production inside cells.
Casanova D, Bouzigues C, Nguyên TL, Ramodiharilafy RO, Bouzhir-Sima L, Gacoin T, Boilot JP, Tharaux PL, Alexandrou A.
Nat Nanotechnol. 2009; 4(9):581-5.
Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle cell disease.
Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, Debbabi H, Galaup A, Maier-Redelsperger M, Vandermeersch S, Scarpa A, Janin A, Levy B, Girot R, Beuzard Y, Leboeuf C, Henri A, Germain S, Dussaule J-C, Tharaux P-L.
J. Clin. Invest. 2008; 118(5):1924-33
Second harmonic microscopy to quantify renal interstitial fibrosis and arterial remodeling.
Strupler M, Hernest M, Fligny C, Martin JL, Tharaux PL, Schanne-Klein MC.
J Biomed Opt. 2008;13(5):054041.
Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers.
Lionnet F, Bachmeyer C, Stankovic K, Tharaux PL, Girot R, Aractingi S.
Br J Haematol. 2008;142(6):991-2
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension.
Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, Coffman TM.
Am J Physiol Renal Physiol. 2008;295(2):F515-24.
Ultrasound imaging of renal vaso-occlusive events in transgenic sickle mice exposed to hypoxic stress.
Bonnin P, Sabaa N, Flamant M, Debbabi H, Tharaux PL.
Ultrasound Med Biol. 2008; 34(7):1076-84.
Variation in natriuretic peptides and mitral flow indexes during successful ventilatory weaning: a preliminary study.
Ait-Oufella H, Tharaux PL, Baudel JL, Vandermeersch S, Meyer P, Tonnellier M, Dussaule JC, Guidet B, Offenstadt G, Maury E.
Intensive Care Med. 2007; 33(7):1183-6.
Second harmonic imaging and scoring of collagen in fibrotic tissues.
Strupler M, Pena A-M, Hernest M, Tharaux P-L, Martin J-L, Beaurepaire E, and Schanne-Klein M-C.
Optics Express. 2007; 15(7):4054-4065
Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells.
Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G.
J Biol Chem. 2007;282(5):2918-28.
Heparin binding EGF is necessary for vasospastic response to endothelin.
Chansel D, Ciroldi M, Vandermeersch S, Jackson LF, Gomez AM, Henrion D, Lee DC, Coffman TM, Richard S, Dussaule JC, Tharaux PL.
FASEB J. 2006; 20(11):1936-8.
Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries.
Lemarie CA, Tharaux PL, Esposito B, Tedgui A, Lehoux S.
Circ Res. 2006; 99(4):434-41.
Urinary endothelin-1 as a marker of renal damage in sickle cell disease.
Tharaux PL, Hagege I, Placier S, Vayssairat M, Kanfer A, Girot R, Dussaule JC.
Nephrol Dial Transplant. 2005;20(11):2408-13.
Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition.
Francois H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, Chatziantoniou C.
FASEB J. 2004;18(7):926-8.
Troponin T as a marker of differentiation revealed by proteomic analysis in renal arterioles.
Pinet F, Poirier F, Fuchs S, Tharaux PL, Caron M, Corvol P, Michel JB, Joubert-Caron R.
FASEB J. 2004;18(3):585-6.
Rho-kinase promotes alloimmune responses by regulating the proliferation and structure of T cells.
Tharaux PL, Bukoski RC, Rocha PN, Crowley SD, Ruiz P, Nataraj C, Howell DN, Kaibuchi K, Spurney RF, Coffman TM. J Immunol. 2003; 171(1):96-105.
Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice.
Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, Dussaule JC.
FASEB J. 2003; 17(2):327-9.
Cutaneous microvascular blood flow and reactivity in patients with homozygous sickle cell anaemia.
Tharaux PL, Girot R, Kanfer A, Dussaule JC, Gaitz JP, Tribout L, Baudot N, Vayssairat M.
Eur J Haematol. 2002;68(6):327-31
Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia.
Chodjania Y, Tharaux PL, Ragueneau I, Dussaule JC, Picker JL, Funck-Brentano C, Jaillon P.
Clin Pharmacol Ther. 2002;71(6):468-78.
Regression of Renal Vascular Fibrosis by Endothelin Receptor Antagonism.
Boffa JJ, Tharaux PL, Dussaule JC and Chatziantoniou C.
Hypertension. 2001; 37(2):490-496.
Angiotensin II activates collagen type I gene through a mechanism involving the MAPK/ERK pathway.
Tharaux PL, Chatziantoniou C, Fakhouri F and Dussaule JC.
Hypertension. 2000; 36(3):330-6.
Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism.
Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC and Chatziantoniou C.
Circulation. 1999; 100(18):1901-1908.
Vascular endothelin-1 gene expression, synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats.
Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R and Dussaule JC.
Circulation. 1999; 99(16):2185-2191.
Evidence for functional ANP receptors in cultured alveolar type II cells.
Tharaux PL, Dussaule JC, Couette S, Clerici C.
Am J Physiol. 1998;274(2 Pt 1):L244-51.
EGF and TGF-beta regulate neutral endopeptidase expression in renal vascular smooth muscle cells.
Tharaux PL, Stefanski A, Ledoux S, Soleilhac JM, Ardaillou R, Dussaule JC.
Am J Physiol. 1997;272(6 Pt 1):C1836-43.
Role of alpha v integrins in mesangial cell adhesion to vitronectin and von Willebrand factor.
Hafdi Z, Lesavre P, Tharaux PL, Bessou G, Baruch D, Halbwachs-Mecarelli L.
Kidney Int. 1997;51(6):1900-7.
Activation of renin synthesis is dependent on intact nitric oxide production.
Tharaux PL, Dussaule JC, Pauti MD, Vassitch Y, Ardaillou R, Chatziantoniou C.
Kidney Int. 1997;51(6):1780-7.
Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy.
Tharaux PL, Dussaule JC, Hubert-Brierre J, Vahanian A, Acar J, Ardaillou R.
Clin Sci (Lond). 1994;87(6):671-7.
Patents
Methods for the prevention and the treatment of extracapillary glomerulonephritis.
Hénique C, Bollée, G, Tharaux P-L. (WO2015EP51275 20150122)PCT IB2014/002603, filed on November 4, 2014 by Inserm Transfert.
Methods for the prevention and the treatment of extracapillary glomerulonephritis. Hénique C, Tharaux P-L. Patent EP14305094.6 (23/01/2014); PCT/EP2015/051275. Filed on January 22, 2015 by Inserm Transfert
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy.
Tharaux P-L, Dhaun N, Sourdon J , Tavitian B. PCT/FR2017/050816. Filed on April 5, 2017 by Inserm Transfert.
Methods to characterize patients suffering from hemolysis
Blanc-Brude O; Tharaux P-L; Boulanger C; Lejeune S; Lionnet F
Patent US2014044735. (09.03.2011) Filed by Inserm-Transfert.
Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis.
Fligny C, Tharaux PL
Patent PCT/EP2011/059100. (01.06.2011). Filed by Inserm-Transfert.
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
Fligny C, Tharaux PL
Patent PCT/EP2010/069130 (8.12.2010). Filed by Inserm-Transfert.
Methods for producing a non human animal model of aortic aneurysm.
Ait Oufella H, Tharaux PL, Tedgui A, Mallat Z.
Patent EP07301521.6 (02.11.2007). Filed by Inserm-Transfert. PCT extension Japan, USA 2010
Use of an EGFR inhibitor for the treatment of glomerulonephritis.
Tharaux P-L, Flamant M.
Patent PCT IB2006/ 003915 (31.10.2006). Filed by Inserm-Transfert. US2010104558 (A1)
2010-04-29 and US8198266 (B2) 2012-06-12.
Reviews
Autophagy in kidney disease and aging: lessons from rodent models.
Lenoir O, Tharaux PL, Huber TB.
Kidney Int. 2016. pii: S0085-2538(16)30173-9. doi: 10.1016/j.kint.2016.04.014.
Update on crescentic glomerulonephritis.
Hénique C, Papista C, Guyonnet L, Lenoir O, Tharaux PL.
Semin Immunopathol. 2014;36(4):479-90
How many ways can a podocyte die?
Tharaux PL, Huber TB.
Semin Nephrol. 2012;32(4):394-404.
Targeting signaling pathways in glomerular diseases.
Henique C, Tharaux PL.
Curr Opin Nephrol Hypertens. 2012;21(4):417-27
Endothelin and the podocyte.
Tharaux PL, Barton M
Clin Kidney J . 2012; 5(1): 17-27
Epidermal growth factor: a new therapeutic target in glomerular disease.
Flamant M, Bollée G, Hénique C, Tharaux PL
Nephrol Dial Transplant. 2012; 27: 1297–1304
Endothelin and podocyte injury in chronic kidney disease.
Fligny C, Barton M, Tharaux PL.
Contrib Nephrol. 2011;172:120-38.
Endothelin in renal injury due to sickle cell disease.
Tharaux PL.
Contrib Nephrol. 2011;172:185-99.
Extracellular matrix alterations in hypertensive vascular remodeling.
Lemarié CA, Tharaux PL, Lehoux S.
J Mol Cell Cardiol. 2009; 48(3):433-9.
New approach of fibrosis by multiphoton microscopy with second harmonic generation.
Hernest M, Pena AM, Strupler M, Beaurepaire E, Martin JL, Schanne-Klein MC, Tharaux PL
Med Sci (Paris). 2006;22(10):820-1.
Exploring type I angiotensin (AT1) receptor functions through gene targeting.
Crowley SD, Tharaux PL, Audoly LP, Coffman TM.
Acta Physiol Scand. 2004;181(4):561-70.
Proteomic analysis of proteins involved in the renal phenotype in renovascular hypertension
Pinet F, Poirier F, Fuchs S, Tharaux PL, Caron M, Corvol P, Michel JB, Joubert-Caron R.
Therapie. 2004;59(1):13-20.
Progression and regression in renal vascular and glomerular fibrosis.
Chatziantoniou C, Boffa JJ, Tharaux PL, Flamant M, Ronco P, Dussaule JC.
Int J Exp Pathol. 2004;85(1):1-11.
Effect of sleep apnea syndrome on the vascular endothelium
Tharaux PL
Rev Neurol (Paris). 2003;159:102-6.
[Vasoactive peptides and the development of renal sclerosis: contribution of transgenes]
Dussaule JC, Boffa JJ, Tharaux PL, Flamant M, Fakhouri F, Chatziantoniou C.
J Soc Biol. 2002;196(4):275-80.
Transgenic mice as a tool to study the renin-angiotensin system.
Tharaux PL, Coffman TM.
Contrib Nephrol. 2001;(135):72-91. Review.
Mechanisms mediating the renal profibrotic actions of vasoactive peptides in transgenic mice.
Dussaule JC, Tharaux PL, Boffa JJ, Fakhouri F, Ardaillou R, Chatziantoniou C.
J Am Soc Nephrol. 2000;11 Suppl 16:S124-8. Review.
Endothelin, renal diseases, and hypertension.
Dussaule JC, Boffa JJ, Tharaux PL, Fakhouri F, Ardaillou R, Chatziantoniou C.
Adv Nephrol Necker Hosp. 2000;30:281-303. Review.
Interest and limits of in vitro studies in renal vascular endocrinology.
Essig M, Ledoux S, Tharaux PL, Chatziantoniou C, Dussaule JC.
Cell Biol Toxicol. 1996;12(4-6):271-4. Review
Other publications ( Editorials and teaching)
[Interactions between the renin-angiotensin system, nitric oxide and endothelin]
Dussaule JC, Tharaux PL, Boffa JJ, Ardaillou R, Chatziantoniou C.
Nephrologie. 1998;19(7):437-41. Review. French.
[Hypokalemia. Etiology, physiopathology, diagnosis, treatment]
Dussaule JC, Tharaux PL.
Rev Prat. 1998;48(15):1697-703. Review. French.
Néphrologie – PL Tharaux.
Ed. du Concours Médical, 1998. ISBN, 2912176409, 9782912176400.
Patents
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy.
Tavitian B, Sourdon J, Dhaun N, Tharaux P-L
Patent PCT/FR2017/050816 (05/04/2017) filed by Inserm Transfert.
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
Hénique C, Tharaux P-L.
Patent PCT/FR2014/052802 (04/11/2014) filed by Inserm Transfert.
Methods for the prevention and the treatment of extracapillary glomerulonephritis
Hénique C, Tharaux P-L.
Patent EP14305094.6 (23/01/2014); PCT/EP2015/051275 (22/01/2015) filed by Inserm Transfert
Methods to characterize patients suffering from hemolysis
Blanc-Brude O, Tharaux P-L, Boulanger C, Lejeune S, Lionnet F
Patent US2014044735. (09.03.2011) Filed by Inserm-Transfert.
Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis.
Fligny C, Tharaux PL
Patent PCT/EP2011/059100. (01.06.2011). Filed by Inserm-Transfert.
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
Fligny C, Tharaux PL
Patent PCT/EP2010/069130 (8.12.2010). Filed by Inserm-Transfert.
Methods for producing a non human animal model of aortic aneurysm.
Ait Oufella H, Tharaux PL, Tedgui A, Mallat Z.
Patent EP07301521.6 (02.11.2007). Filed by Inserm-Transfert. PCT extension Japan, USA 2010
Use of an EGFR inhibitor for the treatment of glomerulonephritis.
Tharaux P-L, Flamant M.
Patent PCT IB2006/ 003915 (31.10.2006). Filed by Inserm-Transfert. US2010104558 (A1)
2010-04-29 and US8198266 (B2) 2012-06-12.
Recent Comments